Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK501704PMID: 30000764
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 9041-08-1
Drug Levels and Effects
Summary of Use during Lactation
Because of the low levels of dalteparin in breastmilk and its large molecular weight of 2000 to 9000 daltons, amounts ingested by the infant are small and it would not be expected to be absorbed from breastmilk by the infant. No special precautions are required.[1]
Drug Levels
Maternal Levels. In two women receiving subcutaneous dalteparin 5000 IU and 10,000 IU daily, respectively, dalteparin was undetectable in breastmilk.[2]
Anti-Xa activity (a measurement of anticoagulant activity) was measured in the milk of 15 patients before and 3 to 4 hours after 4 to 8 days at a daily dosage of 2500 IU subcutaneously. Anti-Xa activity in milk ranged from less than 5 to 37 IU/L which was 2.5 to 22.4% of the simultaneous maternal plasma anti-Xa activity.[3]
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Although not clearly stated, it appears that 15 neonates were breastfed during maternal dalteparin use in one study with no adverse effects reported.[3]
In another report, one mother breastfed her infant for 20 days starting at 7 weeks of age while taking subcutaneous dalteparin 5000 IU subcutaneously twice daily with no adverse effects to her infant.[4]
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Acenocoumarol, Dalteparin, Enoxaparin, Heparin, Rivaroxaban, Warfarin
References
- 1.
- Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: Venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2:3317–59. [PMC free article: PMC6258928] [PubMed: 30482767]
- 2.
- Harenberg J, Leber G, Zimmermann R, et al. Geburtshilfe Frauenheilkd. 1987;47:15–8. [Prevention of thromboembolism with low-molecular weight heparin in pregnancy] [PubMed: 3569823]
- 3.
- Richter C, Sitzmann J, Lang P, et al. Excretion of low molecular weight heparin in human milk. Br J Clin Pharmacol. 2001;52:708–10. [PMC free article: PMC2014571] [PubMed: 11736885]
- 4.
- Lindhoff-Last E, Willeke A, Thalhammer C, et al. Hirudin treatment in a breastfeeding woman. Lancet. 2000;355:467–8. [PubMed: 10841132]
Substance Identification
Substance Name
Dalteparin
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PMCPubMed Central citations
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Review Heparin.[Drugs and Lactation Database (...]Review Heparin.. Drugs and Lactation Database (LactMed®). 2006
- Review Dalteparin sodium.[Expert Opin Pharmacother. 2001]Review Dalteparin sodium.Pineo GF, Hull RD. Expert Opin Pharmacother. 2001 Aug; 2(8):1325-37.
- Low molecular weight heparin for treatment of acute myocardial infarction (FAMI): Fragmin (dalteparin sodium) in acute myocardial infarction.[Indian Heart J. 2000]Low molecular weight heparin for treatment of acute myocardial infarction (FAMI): Fragmin (dalteparin sodium) in acute myocardial infarction.Kakkar VV, Iyengar SS, De Lorenzo F, Hargreaves JR, Kadziola ZA, FAMI Investigator Group. Indian Heart J. 2000 Sep-Oct; 52(5):533-9.
- Dalteparin sodium (fragmin) administration following acute infarction does not affect myocardial perfusion and function in swine.[Cardiovasc Drugs Ther. 2002]Dalteparin sodium (fragmin) administration following acute infarction does not affect myocardial perfusion and function in swine.Scheinowitz M, Heled Y, Chouraqui P, Vered Z, Hayardeni Y, Kotlyar A, Castel D, Livschitz S, Barak V, Savion N, et al. Cardiovasc Drugs Ther. 2002 Jul; 16(4):303-9.
- Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran).[Br J Haematol. 1995]Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran).Ramakrishna R, Manoharan A, Kwan YL, Kyle PW. Br J Haematol. 1995 Nov; 91(3):736-8.
- Dalteparin - Drugs and Lactation Database (LactMed®)Dalteparin - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...